Literature DB >> 26603030

Pipeline embolization device thrombosis induced peri-construct collateral channels.

Albert Ho Yuen Chiu1, Thomas R Marotta2.   

Abstract

More than half a decade of experience and follow-up has now been accumulated with regard to flow diversion as a treatment for intracranial aneurysms; however, many uncertainties, such as the nature of aneurysmal remnants and the meaning of non-regressed, non-perfused aneurysmal masses, are still unknown. Here we discuss a 22-year-old man who presented with a grade 1 subarachnoid hemorrhage secondary to a dissecting right anterior cerebral artery aneurysm who was subsequently treated with a Pipeline Embolization Device construct. After ceasing dual antiplatelet therapy himself, he was found on MRI to have an area of increased aneurysmal remnant reperfusion. This was found to connect to multiple channels which reconstituted flow within the distal construct on angiography. The central area of construct thrombosis could not be visualized on MRI. The finding suggests that non-opacified aneurysmal remnants that have not regressed are biologically active and raises concerns regarding using MRI for long term follow-up. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Aneurysm; Angiography; Blood Flow; Flow Diverter; MRI

Mesh:

Year:  2015        PMID: 26603030     DOI: 10.1136/neurintsurg-2015-012093.rep

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  2 in total

1.  Pipeline embolization device induced collateral channels in elective flow diversion treatment.

Authors:  Yingming Amy Chen; Brian J Drake; Albert Ho Yuen Chiu; Thomas R Marotta
Journal:  BMJ Case Rep       Date:  2016-03-04

2.  Contrast Enhancement of Aneurysm Sac Post-Pipeline Treatment Interpreted as Recanalization.

Authors:  Annie J Tsay; Sara Langan; Scott Simon
Journal:  Cureus       Date:  2017-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.